Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 29.15M shares rose 31.2% year over year, ahead of the +17.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +31.2% holds above the trailing-twelve-month pace of +17.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
29.15M+0.4% QoQ
Last fiscal yearDec 2025
22.43M+5.5% YoY
LTMJun 2026
25.77M+17.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.2%——
1 year+5.5%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
22.43M USD
Year-over-year change
+5.5%
4-year CAGR
+7.9%

Weighted Avg Shares (Diluted) vs competitors

How MDGL compares with its peers on the latest reported figures

  • MDGL's LTM Jun 2026 weighted avg shares (diluted) of 25.77M shares is the lowest of the 7 companies compared; the peer median is 106.72M shares.
  • Its year-over-year change of +17.2% is the 3rd highest of 7, against a peer median of +10.1%.
  • Over three fiscal years its annual growth of +9.4% compares with a peer median of +18.5%.
MDGL Competitors Peer median
Weighted Avg Shares (Diluted) for MDGL and competitors
Company Period LTM YoY 3-year CAGR
IVAInventiva S.A.FY2025186.8M +259.4%+65.2%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026119.47M +13.7%+82.0%
VKTXViking Therapeutics, Inc.LTM Jun 2026114.45M +2.5%+13.6%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
SGMTSagimet Biosciences Inc.LTM Mar 202632.39M +0.9%+13.4%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 202625.77M +17.2%+9.4%
Peer median (excluding MDGL) 106.72M+10.1%+18.5%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000180.13M958.4M
Cost of Revenue0006.23M56.15M
Gross Profit000173.9M902.26M
Gross Margin———96.5%94.1%
Research & Development205.16M245.44M272.35M236.72M388.53M
Selling, General & Admin37.32M48.13M108.15M435.06M813.83M
Operating Expenses242.48M293.57M380.5M671.78M1.2B
Depreciation & Amortization405K467K527K1.1M1.51M
EBITDA(241.44M)(290.92M)(360.39M)(450.13M)(264.47M)
EBITDA Margin———-249.9%-27.6%
Operating Income(242.48M)(293.57M)(380.5M)(497.88M)(300.1M)
Operating Margin———-276.4%-31.3%
Interest Income363K2.19M19.58M46.65M37.36M
Interest Expense03.96M12.71M14.67M22.31M
Other Income / Expenses636K(1.78M)6.87M31.98M11.81M
Income Before Tax(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Pre-Tax Margin———-258.6%-30.1%
Income Tax Expense00000
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Net Margin———-258.6%-30.1%
EPS (Basic)(14.63)(17.23)(19.99)(21.90)(12.85)
EPS (Diluted)(14.63)(17.23)(19.99)(21.90)(12.85)
Weighted Avg Shares16.54M17.14M18.69M21.27M22.43M
Weighted Avg Shares (Diluted)16.54M17.14M18.69M21.27M22.43M

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.